Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

1. iECURE reported positive data for ECUR-506 in OTC deficiency treatment. 2. ECUR-506 shows promising clinical efficacy with good safety profile. 3. BMO upgraded Precision BioSciences, citing positive initial data for ARCUS platform. 4. Potential 100-200% stock upside predicted based on upcoming HBV trial results. 5. DTIL stock rose 25.8% following the positive report.